After the classic animal experiments of Harris (1950), Harris and Johnson (1950) , and McCann and Dhariwal (1966) it was assumed that in man too the hypothalamus controlled the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) independently by means of two releasing hormones, luteinising hormone-releasing hormone (LH-RH) and follicle stimulating hormone-releasing hormone (FSH-RH). However, Schally et al. (1971) were ableto isolate only one gonadotrophin-releasing hormone from many thousands of porcine hypothalami. This hormone (GnRH), a decapeptide, stimulates the secretion of both LH and FSH in animals and in man and can produce differential changes in the secretion of the two gonadotrophins by interaction with the feedback effects of gonadal steroids and inhibin. The latter inhibits FSH secretion. It is probably a polypeptide and is formed in the seminiferous tubules during the final stage of spermatogenesis (which is itself stimulated by FSH).
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GnRH in normal persons

MALES
In normal adults a single bolus of 25 to 500 ,ug of GnRH given intravenously increases LH and FSH secretion in a dose-related manner, although more LH than FSH is secreted (Besser etal., 1972) . The peak circulating levels occur within 10 to 30 minutes and fall gradually over the next few hours. LH remains above baseline values for 4 to 6 hours and FSH for 3 to 5 hours.
With continuous infusion plasma FSH begins to rise within 3 to 10 minutes when GnRH levels are in the range 30 to 221 ng/l. It reaches a plateau at 20 to 30 minutes. The rise in LH begins after 9 to 10 minutes when GnRH levels are 249 to 580 ng/l and reaches its plateau later than FSH. If the infusion is prolonged for several hours the early plateau is followed by a further rise. This has been taken to indicate the presence of two varieties of stored gonadotrophins, of which the more readily releasable variety accounts for the early rise. During the infusion the secretion of both gonadotrophins is pulsatile and the pulses are asynchronous. Between pulses the pituitary is presumably refractory to GnRH so far as the particular gonadotrophin is concerned.
In man feedback effects result from gonadal steroids given in physiological or higher doses and also, presumably, from inhibin in the case of FSH secretion. Men treated with oestrogen (ethinyl oestradiol 30 ,tg/day for three days) show suppression of LH and especially FSH secretion, whether basal or stimulated by GnRH (Mortimer et al., 1973a) . Pituitary responsiveness returns to the pretreatment level three days after withdrawing the oestrogen. Infusion of 17p-oestradiol to produce levels just above the normal male range suppresses the response to GnRH within 30 minutes. Evidently in men the site of negative feedback is at pituitary level. There is as yet no conclusive evidence of positive feedback of oestrogen in the male.
The effects of testosterone preparations on pituitary responsiveness to GnRH are more complex and variable. Supraphysiological doses of testosterone propionate (100 mg/day intramuscularly for 4 to 6 days) suppress basal gonadotrophin levels and the FSH response to GnRH, but there is little change in the LH responses to the releasing hormone. Suppression of the FSH response was also observed by von zur Muhlen and Kobberling (1973) , who continued testosterone oenanthate administration for four weeks. After withdrawal of testosterone secretion of LH recovers more quickly than that of FSH (Lee et al., 1972 (Mortimer et al., 1974a) (Fig. 1) Nillius and Wide (1972) and Yen et al. (1972) . They showed that serial injections of the same dose of GnRH throughout the normal menstrual cycle provoked a relatively small response in the early follicular phase and a greater response in the luteal phase. The greatest response occurred at mid-cycle coincident with the rise in plasma oestradiol.
Oestrogens may also modify hypothalamic function. At mid-cycle there is an eightfold increase in circulating GnRH, as measured by radioimmunoassay (Arimura et al., 1974a; Mortimer et al., 1976a) . Moreover, the intramuscular administration of 1 mg 17f-oestradiol results in a rise in circulating LH, but not FSH, after 48 to 72 hours (Nillius and Wide, 1971 (Tanner, 1958; Franchimont et al., 1974 (Mortimer et al., 1976b) . There is an increase in pituitary responsiveness to injected GnRH, especially of LH secretion, levels reaching a peak between 15 and 45 minutes after the injection. If such patients are treated with 100 gg of ethinyl oestradiol 12-hourly for five days basal serum gonadotrophin levels fall. The response of LH to GnRH is maintained but the peak is diminished and delayed to between 45 and 120 minutes. In contrast, the FSH response is increased by oestrogen treatment. These results suggest that after the menopause FSH secretion is almost maximal and is little affected by further exogenous GnRH; that oestrogens exert a negative feedback action on GnRH so that gonadotrophin levels fall; and that oestrogens sensitise the pituitary to GnRH so far as FSH, but not LH, is concerned (Franchimont et al., 1974) .
In later life some men experience symptoms similar to those of some menopausal women. The so-called 'male climacteric' presents with flushing attacks and lack of energy and of motivation. There is usually no evidence of endocrine disease and plasma testosterone levels may be normal or at the lower limit of normal for adult men. The FSH level is normal unless the total sperm count is low but LH levels may be raised and the LH response to GnRH is exaggerated. It (Palmer et al., 1975; Nillius and Wide, 1975) . These changes are also found in the rare cases of anorexia nervosa in men. Since there is a close correlation between body weight and the age of onset of puberty (Frisch and Revelle, 1970) Katz and Carr (1976) investigated 15 such patients and in some found that basal LH levels were raised, as shown previously by Yen et al. (1970) , and that an exaggerated response occurred after GnRH. Basal FSH levels were always within the normal range. These patients tended to have high oestradiol levels and secondary amenorrhoea and were classified as Group 1. The other patients had normal basal LH values and a normal response to GnRH and tended to have anovulatory cycles; they were classified as Group 2. It remains to be seen whether this classification on the basis of gonadotrophin responses to GnRH is valid or whether it is an artificial distinction based on only one particular aspect of endocrine dysfunction. Whatever the underlying pathology clearly synthesis of pituitary gonadotrophins and the mechanisms for their release are intact and responsive to GnRH stimulation.
The testicular feminisation syndrome is characterised by the resistance of the target organs to the action of testosterone. This leads to the development of individuals who are phenotypically female although genetically male with functioning male gonads. These patients have normal male testosterone levels but high basal gonadotrophin levels, which may not fall with testosterone administration. This suggests that the pituitary (and possibly hypothalamus) is also resistant to its action. As a result the gonadotrophin responses to GnRH may be exaggerated.
Primary dysfunction of the seminiferous tubules gives rise to azoospermia or oligospermia, usually defined as a sperm count of less than 5 x 106/mm3, plasma testosterone levels are normal. As would be expected, LH levels are normal but FSH levels are raised, owing to lack of inhibin, and show an exaggerated response to GnRH.
GnRH therapy MALES
A number of males with delayed puberty or infertility have been treated with GnRH for months or years. Some had proved lesions of the pituitary or hypothalamus, some isolated Gn deficiency, and some were presumed to have isolated FSH deficiency. FSH deficiency was diagnosed on the finding of normal LH and testosterone levels but an FSH response to GnRH which was low or normal despite testicular biopsy evidence of reduced spermatogenesis with maturation arrest.
In many cases there was a rapid increase of potency followed by an increase of sperm count and motility, often well into the normal range. The best results were obtained with 500 jig given eight-hourly by subcutaneous injection. When GnRH was withdrawn there was a reversal of both. With treatment a prepubertal response to GnRH was usually converted to the adult type (Fig. 2) (Zarate et al., 1973; Mortimer et al., 1976b; Mortimer and Besser, 1976) .
Since the improvement in potency is so rapid, often preceding a return of plasma testosterone levels to normal, the GnRH may have some direct action. This is suggested by the experiments of Moss and McCann (1973) and Pfaff (1973) , who found that GnRH increased the sexual responsiveness of female rats even after their ovaries and pituitary had been removed.
PREPUBERTAL FEMALES
GnRH therapy for delayed puberty in females has not been explored to the same extent as in males.
However, in two patients with isolated gonadotrophin deficiency such treatment established a cyclical rhythm of oestrogen excretion (Fig. 3) but without ovulation or menstruation during the first year of treatment. One of them menstruated four weeks after stopping treatment and the other began regular periods with evidence of ovulation when treatment was continued beyond one year.
ADULT FEMALES: INDUCTION OF OVULATION
Initial attempts to induce ovulation with GnRH were disappointing, probably owing to the inadequacy of diagnosis and the use of too small a dose. The introduction of bromocriptine for hyperprolactinaemia and the use of clomiphene and hCG therapy have reduced the indications for therapy with either gonadotrophin or GnRH. However, the latter has been tried in patients with secondary amenorrhoea, especially those due to anorexia nervosa or occurring on withdrawal of depot contraceptive therapy. In one series of eight patients with secondary amenorrhoea from a variety of causes (Akande et al., 1972) GnRH produced a rise in gonadotrophins but ovulation occurred in only one patient, and this began before GnRH was given. The value of GnRH therapy therefore remained in doubt, as also in the case of patients in whom ovulation and pregnancy occurred when they were treated with GnRH and clomiphene simultaneously (Keller, 1973) . Similar limited success was obtained by Zanartu et al. (1974) , who induced ovulation in only 2 out of 16 women with secondary amenorrhoea after the withdrawal of contraceptive drugs.
Brechwoldt et al. (1974) , who used a synthetic analogue, concluded that it was unsuitable for inducing ovulation since its value was limited by pituitary responsiveness. All these studies indicate that the optimal regimen for reliably inducing ovulation remains to be found.
In view of our success in inducing spermatogenesis with 500 mg eight-hourly we used this dose in patients with anorexia nervosa who had had amenorrhoea for five to seven years and were clomiphene unresponsive . The patients were either at their ideal body weight or slightly below it. Basal urinary oestrogens were within the normal range for the early follicular phase. Initially, basal serum gonadotrophins were low or absent but increased during seven days of therapy as did the urinary oestrogens, which rose (0) (WEEKS) (Reproduced by kindpermission of the Editor and Publishers, Clinical Neurology, 1977, in press.) to the maximum of the range encountered at midcycle. Therapy was then discontinued and the gonadotrophin levels became low or undetectable with a fall in urinary oestrogens (Fig. 4) . More treatment was given on days 12-14 and this was followed between days 18 and 28 by a small rise in gonadotrophins and a further rise in oestrogen excretion. These results indicated that the patients had adequate pituitary LH and FSH reserve although the release of the gonadotrophins was impaired in the absence of therapy due to a persistent deficiency of endogenous GnRH. The spontaneous release of gonadotrophins between days 18 and 28 in the absence of treatment indicated that there had been positive feedback by the increased levels of circulating oestrogens at the hypothalamicpituitary level. After treatment one patient menstruated for the first time in six years although there was no biochemical evidence of ovulation in any of the four patients. Two patients subsequently became responsive to clomiphene with a return of ovulation, and others ovulated after a more prolonged course of . No patient reported an increase in libido. Nillius and Wide (1975) also succeeded in inducing ovulation with GnRH alone although they noted that hCG may be a useful addition during the second half of the expected cycle to facilitate pregnancy if there is evidence of luteal phase insufficiency. Since the oestrogen and progesterone responses in these studies resemble those seen in the normal menstrual cycle it would seem that GnRH 500 ,ug subcutaneously eight-hourly preserves the normal feedback relationship of the hypothalamic-pituitaryovarian axis. It is hoped that this will prevent the occurrence of the hyperstimulation syndrome and the multiple births which are far too commonly encountered with human menopausal gonadotrophin therapy. found antibody formation. But this has been reported with intermittent therapy in a man, whose sexual function deteriorated as a result (Van Loon and Brown, 1975) . Patients should therefore be regularly screened for antibody formation during long-term treatment.
ANALOGUES OF GnRH
The half-life of GnRH in the circulation is about five minutes, although the ensuing gonadotrophin levels are raised for several hours. A number of analogues have been synthesised which are more active and more resistant to enzymic degradation (Arimura et al., 1974b; Vilchez-Martinez et al., 1974) . One such analogue instilled intranasally raises the gonadotrophin levels for 12 to 24 hours in man. Some analogues are effective when given by the mouth, nose, rectum, or vagina, and probably oral or nasal administration will become the standard method. Derivatives with predominantly inhibitory effects on gonadotrophin secretion are being developed and may provide a means of non-steroidal contraception.
Methods of assay RADIOIMMUNOASSAY
Hitherto radioimmunoassays for GnRH have been too insensitive for measuring basal plasma levels. This problem has now been overcome (Mortimer et al., 1976a) with the use of Vycor (a leached silica glass) for the extraction, but some of the GnRH is eluted before the major peak. A similar fractionation occurs with methanol extraction, but this does not necessarily indicate that plasma GnRH includes a 'big' or protein-bound form. The res-ults obtained with our new method are much lower than those of other authors (Table) and further work is required to determine whether these results represent intact endogenous GnRH or biologically inactive fragments.
BIOASSAY
There have been few attempts to measure GnRH in the peripheral circulation by in-vivo bioassay, which is unlikely to achieve the sensitivity of the radioimmunoassay. In the method of Reichlin (Malacara et al., 1972) , the gonadotrophins are extracted from 40 ml of plasma with methanol and, after transfer into saline, injected into an ovariectomised rat. GnRH activity is assessed by the increase of plasma LH values 10 minutes after injection. The latest assay of these authors is based on direct injection of 1 ml of human plasma (Seyler and Reichlin, 1974) . However, this gives GnRH concentrations of 10-50 ng/l in normal men compared with 0.2 ng/l found in our immunoassay, and up to 400 ng/l in normal women compared with 9 ng/l by our method.
We have developed an in-vitro bioassay based on the perfused pituitary cell column technique described by Lowry (1974 (Mortimer et al., 1976a) . Results given by this bioassay are consistent with those obtained by radioimmunoassay (Yeo et al., 1977) .
